Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.

Cohen, Victor

Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research May 2003 - 1611-5 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1078-0432


Adenocarcinoma--drug therapy
Adult
Aged
Alleles
Antineoplastic Agents--therapeutic use
Capecitabine
Colorectal Neoplasms--drug therapy
DNA, Neoplasm--genetics
Deoxycytidine--analogs & derivatives
Female
Fluorouracil--therapeutic use
Genotype
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2)--genetics
Middle Aged
Neoplasm Staging
Polymorphism, Genetic
Predictive Value of Tests